If a loss of MLH1 and PMS2 is detected by IHC in tumor tissue, the additional presence of a BRAF V600E variant in tumor tissue or of promotor methylation of MLH1 likely indicates a sporadic CRC case. This evidence concerns the gene MLH1 and neoplasm.